Detection of ARV-Resistant Mutants in HIV-1-Infected Individuals in a Context of Systematic Switching to an Association Based on Dolutegravir in Abidjan, C？te d’Ivoire
The emergence of antiretroviral resistance mutations represents a major threat to the achievement of national and global goals for the elimination of HIV-1 infection. The global strategy in 2019 in Côte d'Ivoire is a new national policy for the management of people living with HIV with the administration of dolutegravir (DTG)-based fixed-dose combination. The aim of our study was to evaluate HIV-1 resistance to antiretrovirals (ARVs) in infected adult subjects in Côte d’Ivoire in the context of a systematic switch to a DTG-based combination. Between February 2022 and October 2023, a cross-sectional survey with random sampling was conducted in 06 services caring for people living with HIV. A total of 139 participants were included in the study. Adults with a viral load ≥ 1000 copies/mL were tested for HIV-1 ARV resistance mutations. Molecular analyses were performed using protocol of ANRS-MIE (National Agency for Research on AIDS and emerging infectious diseases). The interpretation is performed by HIVGRAD (https://www.hiv-grade.de/cms/grade/). The frequencies of HIV-1 resistance to non-nucleotide reverse transcriptase inhibitors (NNRTIs), nucleotide reverse transcriptase inhibitors (NRTIs), integrase inhibitors (IINTs) and protease inhibitors (PIs) were 82%, 73%, 19% and 11% respectively. The main mutations observed in the different classes were K103N (45%), M184V (64%), E157Q (19%) and L10V/M46I/A71V/I54V (6%) respectively. This study reveals the emergence of resistance to DTG-based fixed-dose combinations, favored by high rates of resistance to NRTIs and NNRTIs. This finding underlines the need for enhanced viral load monitoring and HIV-1 genotyping tests to guide the choice of NRTIs for combination therapy. In addition, monitoring for mutations to second-generation NRTIs is essential, given the scale-up of DTG-based regimens currently underway in Côte d’Ivoire.
References
[1]
ONUSIDA (2023) Fiche d’information. Dernières statistiques sur l’état de l’épidémie de sida. https://www.unaids.org/fr/resources/fact-sheet
[2]
WHO (2021) HIV Drug Resistance Report. https://www.who.int/publications-detail-redirect/9789240038608
[3]
WHO (2016) World Health Organization: Consolidated guidelines. Genève. https://scholar.google.com/scholar_lookup?title=Consolidated+guidelines+on+the+use+of+antiretroviral+drugs+for+treating+and+preventing+HIV+infection.+Recommendations+for+a+public+health+approach+-+Second+edition.+2nd+ed&publication_year=2018&
[4]
Dechi, J.J.R., Toni, T.D., Cisse-Camara, M., Philippe, N.J.L., Ake, A.J.A., Siransy, K.L., et al. (2022) Nucleoside Reverse Transcriptase Inhibitors Resistance in Children and Adults with Virological Failure in a Context of Systematic Switching to a Dolutegravir-Based Combination. Biochemistry and Molecular Biology, 7, 70-74.
[5]
Kouamou, V., Manasa, J., Katzenstein, D., McGregor, A.M., Ndhlovu, C.E. and Makadzange, A.T. (2019) Drug Resistance and Optimizing Dolutegravir Regimens for Adolescents and Young Adults Failing Antiretroviral Therapy. AIDS, 33, 1729-1737. https://doi.org/10.1097/QAD.0000000000002284
[6]
Bivigou-Mboumba, B., Iroungou, B.A., Moussavou-Boundzanga, P., Mangouka, L.G., Akombi, F.L., Bouassa-Bouassa, A., Francois-Souquière, S. and Nzenze, J.R. (2022) HIV Genetic Diversity, Virological Failure, and Drug Resistance in Libreville, Capital of Gabon, before a Total Dolutegravir-Based Regimen Transition. World Journal of AIDS, 12, 156-168. https://doi.org/10.4236/wja.2022.123012
[7]
Appah, A., Beelen, C.J., Kirkby, D., Dong, W., Shahid, A., Foley, B., Mensah, M., Ganu, V., Puplampu, P., Amoah, L.E., et al. (2023) Molecular Epidemiology of HIV-1 in Ghana: Subtype Distribution, Drug Resistance and Coreceptor Usage. Viruses, 15, 128. https://doi.org/10.3390/v15010128
[8]
Clutter, D.S., Jordan, M.R., Bertagnolio, S. and Shafer, R.W. (2016) HIV-1 Drug Resistance and Resistance Testing. Infection, Genetics and Evolution, 46, 292-307. https://doi.org/10.1016/j.meegid.2016.08.031
[9]
Fily, F., Ayikobua, E., Ssemwanga, D., Nicholas, S., Kaleebu, P., Delaugerre, C., Pasquier, E., Amoros Quiles, I., Balkan, S. and Schramm, B. (2018) HIV-1 Drug Resistance Testing at Second-Line Regimen Failure in Arua, Uganda: Avoiding Unnecessary Switch to an Empiric Third-Line. Tropical Medicine & International Health, 23, 1075-1083. https://doi.org/10.1111/tmi.13131
[10]
Salou, M., Butel, C., Comlan, A.S., Konou, A.A., Tegueni, K., Ehlan, A., Lack, F., Dossim, S., Ayouba, A., Delaporte, E., Dagnra, A.Y. and Peeters, M. (2020) Challenges of Scale-Up to Dolutegravir-Based Regimens in Sub-Saharan Africa. AIDS, 34, 783-787. https://doi.org/10.1097/QAD.0000000000002470
[11]
Maena, J., Banke-Thomas, A., Mukiza, N., Kuteesa, C.N., Kakumba, R.M., Kataike, H., et al. (2021) Determinants of Viral Load Non-Suppression among Adolescents in Mbale District, Eastern Rural Uganda. AIDS Research and Therapy, 18, Article No. 91. https://doi.org/10.1186/s12981-021-00408-1
[12]
Koay, W.L.A., Kose-Otieno, J. and Rakhmanina, N. (2021) HIV Drug Resistance in Children and Adolescents: Always a Challenge? Current Epidemiology Reports, 8, 97-107. https://doi.org/10.1007/s40471-021-00268-3
[13]
Oluniyi, P.E., Ajogbasile, F.V., Zhou, S., Fred-Akintunwa, I., Polyak, C.S., Ake, J.A., Tovanabutra, S., Iroezindu, M., Rolland, M. and Happi, C.T. (2022) HIV-1 Drug Resistance and Genetic Diversity in a Cohort of People with HIV-1 in Nigeria. AIDS, 36, 137-146. https://doi.org/10.1097/QAD.0000000000003098
[14]
Musengimana, G., Tuyishime, E., Kiromera, A., Malamba, S.S., Mulindabigwi, A., Habimana, M.R., Baribwira, C., Ribakare, M., Habimana, S.D., DeVos, J., Mwesigwa, R.C.N., Kayirangwa, E., Semuhore, J.M., Rwibasira, G.N., Suthar, A.B. and Remera, E. (2022) Acquired HIV Drug Resistance among Adults Living with HIV Receiving First-Line Antiretroviral Therapy in Rwanda: A Cross-Sectional Nationally Representative Survey. Antiviral Therapy, 27. https://doi.org/10.1177/13596535221102690
[15]
Bwire, G.M., Aiko, B.G., Mosha, I.H., Kilapilo, M.S., Mangara, A., Kazonda, P., et al. (2023) High Viral Suppression and Detection of Dolutegravir-Resistance Associated Mutations in Treatment-Experienced Tanzanian Adults Living with HIV-1 in Dar es Salaam. Scientific Reports, 13, Article No. 20493. https://doi.org/10.1038/s41598-023-47795-1
[16]
Marcelin, A.G., Grude, M., Charpentier, C., Bellecave, P., Le Guen, L., Pallier, C., et al. (2019) Resistance to Integrase Inhibitors: A National Study in HIV-1-Infected Treatment-Naive and-Experienced Patients. Journal of Antimicrobial Chemotherapy, 74, 1368-1375. https://doi.org/10.1093/jac/dkz021
[17]
Hocqueloux, L., Raffi, F., Prazuck, T., Bernard, L., Sunder, S., Esnault, J.L., et al. (2019) Dolutegravir Monotherapy versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living with Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial. Clinical Infectious Diseases, 69, 1498-1505. https://doi.org/10.1093/cid/ciy1132
[18]
Blanco, J.L., Rojas, J., Paredes, R., Negredo, E., Mallolas, J., Casadella, M., et al. (2018) Dolutegravir-Based Maintenance Monotherapy versus Dual Therapy with Lamivudine: A Planned 24 Weeks Analysis of the DOLAM Randomized Clinical Trial. Journal of Antimicrobial Chemotherapy, 73, 1965-1971. https://doi.org/10.1093/jac/dky093
